NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $7.91 -3.44 (-30.31%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$8.21 +0.30 (+3.75%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.73▼$10.0050-Day Range$7.91▼$12.1552-Week Range$6.72▼$20.56Volume3.73 million shsAverage Volume319,476 shsMarket Capitalization$146.56 millionP/E RatioN/ADividend YieldN/APrice Target$42.89Consensus RatingModerate Buy Company Overview Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders. Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation. The company has also received orphan drug and Fast Track designations for lenabasum in systemic sclerosis and dermatomyositis, underscoring regulatory recognition of its potential to address conditions with limited treatment options. Corbus continues to explore additional indications for its pipeline operations, seeking partnerships and collaborations to support late-stage development and eventual commercialization. Founded in 2006 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals primarily serves patients in North America and Europe through its clinical trial network. Under the leadership of President and Chief Executive Officer Kenneth T. Leonard and Chief Financial Officer Robert J. Conway, the company remains focused on advancing innovative therapies for complex inflammatory diseases and positioning itself as a leader in resolution pharmacology.AI Generated. May Contain Errors. Read More Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCRBP MarketRank™: Corbus Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 439th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialCorbus Pharmaceuticals has a consensus price target of $42.89, representing about 442.2% upside from its current price of $7.91.Amount of Analyst CoverageCorbus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.83) to ($6.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.23% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.61.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 4.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.22 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest6 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBP Stock News HeadlinesCorbus Pharmaceuticals' CRB-701 Study Update Points to Promise in HPV-Linked Cancers2 hours ago | americanbankingnews.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO TranscriptMay 26 at 2:03 PM | seekingalpha.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 27 at 1:00 AM | Paradigm Press (Ad)Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical CancersMay 26 at 7:00 AM | globenewswire.comMizuho Issues Positive Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock PriceMay 23, 2026 | americanbankingnews.comCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallMay 21, 2026 | globenewswire.comCorbus Pharmaceuticals (NASDAQ:CRBP) & Lexeo Therapeutics (NASDAQ:LXEO) Head-To-Head SurveyMay 17, 2026 | americanbankingnews.comCorbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at GuggenheimMay 16, 2026 | americanbankingnews.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $8.14 at the beginning of 2026. Since then, CRBP stock has decreased by 2.8% and is now trading at $7.91. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings data on Tuesday, May, 12th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.03. When did Corbus Pharmaceuticals IPO? Corbus Pharmaceuticals (CRBP) raised $20 million in an IPO on Thursday, April 16th 2015. The company issued 20,206,636 shares at a price of $1.00 per share. Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' top institutional investors include Orbimed Advisors LLC (9.38%), Renaissance Technologies LLC (1.87%), Exome Asset Management LLC (1.26%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Ian Hodgson, Anne Altmeyer and John Kenneth Jenkins. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings5/12/2026Today5/27/2026Study result6/01/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRBP's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees40Year Founded2009Price Target and Rating Average Price Target for Corbus Pharmaceuticals$42.89 High Price Target$54.00 Low Price Target$28.00 Potential Upside/Downside+442.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($5.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.89% Return on Assets-61.78% Debt Debt-to-Equity RatioN/A Current Ratio7.92 Quick Ratio7.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.82 per share Price / Book1.16Miscellaneous Outstanding Shares18,528,000Free Float17,880,000Market Cap$146.56 million OptionableOptionable Beta2.68 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CRBP) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
